Cancer-cell-biomimetic nanoparticles for enhanced prostate cancer therapy

BACKGROUND: The targeted delivery of traditional chemotherapeutic drugs by nanocarriers has become an effective way to reduce drug toxicity and improve antitumor effects. However, nanocarriers are easily recognized and cleared by the immune system after entering the body, thereby reducing their therapeutic effect. RESULTS: In this work, based on the biomimetic design concept, a tumor cell membrane-coated nanoplatform (TCM/SCM/DTX) was fabricated for evading the clearance of the immune system and efficiently targeting tumor tissues to achieve efficient drug accumulation in tumor tissues. In vitro cell experiments, TCM/SCM/DTX could effectively enter prostate tumor cells and showed a good in vitro anti-tumor effect. After administration, TCM/SCM/DTX could efficiently accumulate into tumor tissue while achieving long-term blood circulation. The in vivo anti-tumor results proved its effective tumor growth inhibitory effect, and the immunohistochemical results also proved that TCM/SCM/DTX significantly reduced the tissue and organ toxicity of DTX. CONCLUSIONS: This study shows that the prostate tumor cell membrane-coated biomimetic nanocarriers can effectively deliver traditional chemotherapeutic drugs to prostate cancer tissue, which provides a new strategy for precise and efficient chemotherapy of prostate cancer, especially advanced prostate cancer. (c) 2023 Society of Chemical Industry (SCI).